Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

RM. Smith, RB. Jones, U. Specks, S. Bond, M. Nodale, R. Al-Jayyousi, J. Andrews, A. Bruchfeld, B. Camilleri, S. Carette, CK. Cheung, V. Derebail, T. Doulton, A. Ferraro, L. Forbess, S. Fujimoto, S. Furuta, O. Gewurz-Singer, L. Harper, T....

. 2023 ; 82 (7) : 937-944. [pub] 20230323

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu randomizované kontrolované studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010943

Grantová podpora
Wellcome Trust - United Kingdom
U54 AR057319 NIAMS NIH HHS - United States
U54 RR019497 NCRR NIH HHS - United States

OBJECTIVE: Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality. The RITAZAREM trial compared the efficacy of repeat-dose rituximab to daily oral azathioprine for prevention of relapse in patients with relapsing AAV in whom remission was reinduced with rituximab. METHODS: RITAZAREM was an international randomised controlled, open-label, superiority trial that recruited 188 patients at the time of an AAV relapse from 29 centres in seven countries between April 2013 and November 2016. All patients received rituximab and glucocorticoids to reinduce remission. Patients achieving remission by 4 months were randomised to receive rituximab intravenously (1000 mg every 4 months, through month 20) (85 patients) or azathioprine (2 mg/kg/day, tapered after month 24) (85 patients) and followed for a minimum of 36 months. The primary outcome was time to disease relapse (either major or minor relapse). RESULTS: Rituximab was superior to azathioprine in preventing relapse: HR 0.41; 95% CI 0.27 to 0.61, p<0.001. 19/85 (22%) patients in the rituximab group and 31/85 (36%) in the azathioprine group experienced at least one serious adverse event during the treatment period. There were no differences in rates of hypogammaglobulinaemia or infection between groups. CONCLUSIONS: Following induction of remission with rituximab, fixed-interval, repeat-dose rituximab was superior to azathioprine for preventing disease relapse in patients with AAV with a prior history of relapse. TRIAL REGISTRATION NUMBER: NCT01697267; ClinicalTrials.gov identifier.

1st Department of Internal Medicine Kyorin University School of Medicine Tokyo Japan

Allergy and Clinical Immunology Chiba University Chiba Japan

Cambridge Clinical Trials Unit Cambridge University Hospitals NHS Foundation Trust Cambridge UK

Hemovascular Medicine and Artificial Organs Faculty of Medicine University of Miyazaki Miyazaki Japan

Medicine Addenbrooke's Hospital Cambridge UK

Medicine Charles University Praha Czech Republic

Medicine Imperial College London London UK

Medicine McMaster University Hamilton Ontario Canada

Medicine Rheumatology University of Pittsburg Pittsburg Pennsylvania USA

Medicine Royal Brisbane and Women's Hospital Herston Queensland Australia

Medicine University of Cambridge Cambridge UK

Medicine University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

Medicine University of Pennsylvania Philadelphia Pennsylvania USA

Mount Sinai Hospital University of Toronto Toronto Ontario Canada

Nephrology Australian National University Medical School Canberra Australian Capital Territory Australia

Nephrology East Kent Hospitals University NHS Foundation Trust Canterbury UK

Nephrology Ipswich Hospital NHS Trust Ipswich UK

Nephrology Karolinska University Hospital and Karolinska Institute Stockholm Sweden

Nephrology Nottingham University Hospitals NHS Trust Nottingham UK

Nephrology Royal Adelaide Hospital Adelaide South Australia Australia

Nephrology South Tees Hospitals NHS Foundation Trust Middlesbrough UK

Nephrology University Hospitals of Leicester NHS Trust Leicester UK

Nephrology University of Birmingham Birmingham UK

Nephrology University of Leicester Leicester UK

NIHR Leeds Musculoskeletal Biomedical Research Unit Leeds Teaching Hospitals Trust Leeds UK

Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science University of Oxford Oxford UK

Pulmonary Medicine Mayo Clinic Rochester Minnesota USA

Renal Medicine Addenbrooke's Hospital Cambridge UK

Rheumatic and Immunologic Diseases Cleveland Clinic Foundation Cleveland Ohio USA

Rheumatology Cedars Sinai Medical Center Los Angeles California USA

Rheumatology Dudley Group of Hospitals NHS Trust Dudley UK

Rheumatology Hospital for Special Surgery New York New York USA

Rheumatology Nottingham University Hospital Nottingham UK

Rheumatology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

Rheumatology The University of Utah Salt Lake City Utah USA

Rheumatology University of Michigan Ann Arbor Michigan USA

Rheumatology University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA

Rheumatology University of Toronto Toronto Ontario Canada

The Clinical and Translational Research Center Kyoto Prefectural University of Medicine Kyoto Japan

UNC Kidney Center Division of Nephrology and Hypertension University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

Vasculitis and lupus clinic Cambridge University Hospitals NHS Foundation Trust Cambridge UK

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010943
003      
CZ-PrNML
005      
20230801132718.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/ard-2022-223559 $2 doi
035    __
$a (PubMed)36958796
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Smith, Rona M $u Medicine, University of Cambridge, Cambridge, UK rms50@cam.ac.uk $1 https://orcid.org/0000000274385156
245    10
$a Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial / $c RM. Smith, RB. Jones, U. Specks, S. Bond, M. Nodale, R. Al-Jayyousi, J. Andrews, A. Bruchfeld, B. Camilleri, S. Carette, CK. Cheung, V. Derebail, T. Doulton, A. Ferraro, L. Forbess, S. Fujimoto, S. Furuta, O. Gewurz-Singer, L. Harper, T. Ito-Ihara, N. Khalidi, R. Klocke, C. Koening, Y. Komagata, C. Langford, P. Lanyon, R. Luqmani, C. McAlear, LW. Moreland, K. Mynard, P. Nachman, C. Pagnoux, CA. Peh, C. Pusey, D. Ranganathan, RL. Rhee, R. Spiera, AG. Sreih, V. Tesar, G. Walters, C. Wroe, D. Jayne, PA. Merkel, RITAZAREM co-investigators
520    9_
$a OBJECTIVE: Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse. Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality. The RITAZAREM trial compared the efficacy of repeat-dose rituximab to daily oral azathioprine for prevention of relapse in patients with relapsing AAV in whom remission was reinduced with rituximab. METHODS: RITAZAREM was an international randomised controlled, open-label, superiority trial that recruited 188 patients at the time of an AAV relapse from 29 centres in seven countries between April 2013 and November 2016. All patients received rituximab and glucocorticoids to reinduce remission. Patients achieving remission by 4 months were randomised to receive rituximab intravenously (1000 mg every 4 months, through month 20) (85 patients) or azathioprine (2 mg/kg/day, tapered after month 24) (85 patients) and followed for a minimum of 36 months. The primary outcome was time to disease relapse (either major or minor relapse). RESULTS: Rituximab was superior to azathioprine in preventing relapse: HR 0.41; 95% CI 0.27 to 0.61, p<0.001. 19/85 (22%) patients in the rituximab group and 31/85 (36%) in the azathioprine group experienced at least one serious adverse event during the treatment period. There were no differences in rates of hypogammaglobulinaemia or infection between groups. CONCLUSIONS: Following induction of remission with rituximab, fixed-interval, repeat-dose rituximab was superior to azathioprine for preventing disease relapse in patients with AAV with a prior history of relapse. TRIAL REGISTRATION NUMBER: NCT01697267; ClinicalTrials.gov identifier.
650    _2
$a lidé $7 D006801
650    12
$a azathioprin $x terapeutické užití $7 D001379
650    _2
$a rituximab $x terapeutické užití $7 D000069283
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    12
$a ANCA-asociované vaskulitidy $x farmakoterapie $7 D056648
650    _2
$a recidiva $7 D012008
650    _2
$a indukce remise $7 D012074
650    _2
$a výsledek terapie $7 D016896
650    _2
$a cyklofosfamid $x terapeutické užití $7 D003520
650    _2
$a protilátky proti cytoplazmě neutrofilů $7 D019268
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jones, Rachel B $u Renal Medicine, Addenbrooke's Hospital, Cambridge, UK
700    1_
$a Specks, Ulrich $u Pulmonary Medicine, Mayo Clinic, Rochester, Minnesota, USA
700    1_
$a Bond, Simon $u Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
700    1_
$a Nodale, Marianna $u Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK $1 https://orcid.org/0000000203338918
700    1_
$a Al-Jayyousi, Reem $u Nephrology, University Hospitals of Leicester NHS Trust, Leicester, UK
700    1_
$a Andrews, Jacqueline $u NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK
700    1_
$a Bruchfeld, Annette $u Nephrology, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden
700    1_
$a Camilleri, Brian $u Nephrology, Ipswich Hospital NHS Trust, Ipswich, UK
700    1_
$a Carette, Simon $u Rheumatology, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Cheung, Chee Kay $u Nephrology, University of Leicester, Leicester, UK
700    1_
$a Derebail, Vimal $u Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
700    1_
$a Doulton, Tim $u Nephrology, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK
700    1_
$a Ferraro, Alastair $u Nephrology, Nottingham University Hospitals NHS Trust, Nottingham, UK
700    1_
$a Forbess, Lindsy $u Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA
700    1_
$a Fujimoto, Shouichi $u Hemovascular Medicine and Artificial Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan $1 https://orcid.org/0000000200254030
700    1_
$a Furuta, Shunsuke $u Allergy and Clinical Immunology, Chiba University, Chiba, Japan $1 https://orcid.org/0000000324822685
700    1_
$a Gewurz-Singer, Ora $u Rheumatology, University of Michigan, Ann Arbor, Michigan, USA
700    1_
$a Harper, Lorraine $u Nephrology, University of Birmingham, Birmingham, UK $1 https://orcid.org/0000000313439234
700    1_
$a Ito-Ihara, Toshiko $u The Clinical and Translational Research Center, Kyoto Prefectural University of Medicine, Kyoto, Japan
700    1_
$a Khalidi, Nader $u Medicine, McMaster University, Hamilton, Ontario, Canada $1 https://orcid.org/0000000282702617
700    1_
$a Klocke, Rainer $u Rheumatology, Dudley Group of Hospitals NHS Trust, Dudley, UK
700    1_
$a Koening, Curry $u Rheumatology, The University of Utah, Salt Lake City, Utah, USA
700    1_
$a Komagata, Yoshinori $u First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
700    1_
$a Langford, Carol $u Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, Ohio, USA
700    1_
$a Lanyon, Peter $u Rheumatology, Nottingham University Hospital, Nottingham, UK
700    1_
$a Luqmani, Raashid $u Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NDORMs), University of Oxford, Oxford, UK
700    1_
$a McAlear, Carol $u Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
700    1_
$a Moreland, Larry W $u Medicine/Rheumatology, University of Pittsburg, Pittsburg, Pennsylvania, USA
700    1_
$a Mynard, Kim $u Vasculitis and lupus clinic, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
700    1_
$a Nachman, Patrick $u UNC Kidney Center, Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
700    1_
$a Pagnoux, Christian $u Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
700    1_
$a Peh, Chen Au $u Nephrology, Royal Adelaide Hospital, Adelaide, South Australia, Australia
700    1_
$a Pusey, Charles $u Medicine, Imperial College London, London, UK
700    1_
$a Ranganathan, Dwarakanathan $u Medicine, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
700    1_
$a Rhee, Rennie L $u Rheumatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA $1 https://orcid.org/0000000249070304
700    1_
$a Spiera, Robert $u Rheumatology, Hospital for Special Surgery, New York, New York, USA $1 https://orcid.org/0000000329116800
700    1_
$a Sreih, Antoine G $u Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
700    1_
$a Tesar, Vladamir $u Medicine, Charles University, Praha, Czech Republic
700    1_
$a Walters, Giles $u Nephrology, Australian National University Medical School, Canberra, Australian Capital Territory, Australia $1 https://orcid.org/0000000348549353
700    1_
$a Wroe, Caroline $u Nephrology, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK
700    1_
$a Jayne, David $u Medicine, Addenbrooke's Hospital, Cambridge, UK $1 https://orcid.org/0000000217120637
700    1_
$a Merkel, Peter A $u Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
710    2_
$a RITAZAREM co-investigators
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 82, č. 7 (2023), s. 937-944
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36958796 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132715 $b ABA008
999    __
$a ok $b bmc $g 1963391 $s 1197208
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 82 $c 7 $d 937-944 $e 20230323 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
GRA    __
$p Wellcome Trust $2 United Kingdom
GRA    __
$a U54 AR057319 $p NIAMS NIH HHS $2 United States
GRA    __
$a U54 RR019497 $p NCRR NIH HHS $2 United States
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace